Featured Publications
Genotype-Selective Combination Therapies for Melanoma Identified by High-Throughput Drug Screening
Held MA, Langdon CG, Platt JT, Graham-Steed T, Liu Z, Chakraborty A, Bacchiocchi A, Koo A, Haskins JW, Bosenberg MW, Stern DF. Genotype-Selective Combination Therapies for Melanoma Identified by High-Throughput Drug Screening. Cancer Discovery 2013, 3: 52-67. PMID: 23239741, PMCID: PMC3546137, DOI: 10.1158/2159-8290.cd-12-0408.Peer-Reviewed Original ResearchConceptsMutant BRAF melanomaCyclin-dependent kinase inhibitorBRAF melanomaSmall molecule inhibitorsHigh-throughput drug screeningDrug screeningEGF receptorCombination therapyDrug combinationsMelanoma culturesContext of genotypePairwise combinationsResistance phenotypeCombinatorial drug screeningUnique treatment regimensCombination of statinsVivo xenograftsKinase inhibitorsMutant BRAFMutationsEfficacious drug combinationsPartial responseTreatment regimensRAS mutationsBRAF mutations
1996
Heregulin-Induced Growth Factor Receptor Signaling and Breast Carcinogenesis.
Riese D, Stern D. Heregulin-Induced Growth Factor Receptor Signaling and Breast Carcinogenesis. 1996 DOI: 10.21236/ada315700.Peer-Reviewed Original ResearchErbB family receptorsCellular signaling proteinsGrowth factor receptor signalingFamily receptorsBa/F3 cell lineCell linesEGF-like growth factorNeu differentiation factorEpidermal growth factor (EGF) familyGrowth factor familySignaling proteinsFactor familyGrowth factor alphaCellular responsesReceptor phosphorylationReceptor signalingErbB familyDistinct activitiesPairwise combinationsDifferentiation factorEGFBetacellulinHeregulinGrowth factorProtein